Global Basal Insulin (Long-Acting Insulin) Market - 2023-2030

Market Overview

The Global Basal Insulin (Long-Acting Insulin) Market reached US$ 234.8 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 331.6 million by 2030. The global basal insulin (long-acting insulin) market is expected to exhibit a CAGR of 4.5% during the forecast period (2023-2030).

The rising incidence of diabetes, promising repayment guidelines, and market developments like product introduction, product authorizations, consolidations, investments, partnerships, and expansion among others are boosting the global basal insulin (long-acting insulin) market growth. The key players in this market include Novo Nordisk AS, Sanofi Aventis, and Biocon among others.

Market Dynamics

An Increase In Diabetes Cases Drives The Growth Of The Basal Insulin (Long-Acting Insulin) Market.

The growing cases of diabetes are driving the global basal insulin (long-acting insulin) market growth. For instance, according to the Access to Medicine Foundation, diabetes increases rapidly globally, inducing 6.7 million deaths annually. Access to insulin is an increasingly critical multinational health importance. The number of individuals with diabetes globally is anticipated to surpass 643 million by 2030, and 783 million by 2045 rising most quickly in low- and middle-income countries (LMICs), where there is stark inequity in access to insulin.

Presence Of Various Patient Assistance Programs Creates Lucrative Opportunities For Market Growth.

The presence of various patient assistance programs presents the market with prospective growth opportunities in the upcoming years. For instance, Lilly Cares Program, Novo Nordisk Patient Assistance Program (PAP) NovoCare, Insulins ValYOU Savings Program, Direct Purchase Program, and Insulin Glargine Follow-On Biologic among others provide low-cost or repayment on insulin purchases.

Stringent Regulatory Authorities Hamper the Growth of the Market.

The presence of stringent regulatory authorities controlling the development and commercialization of insulin products slows the global basal insulin (long-acting insulin) market growth. For instance, the major regulatory authorities controlling the development and commercialization of insulin include the FDA and EMA. Above mentioned factors are limiting the basal insulin (long-acting insulin) market growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global basal insulin (long-acting insulin) market, owing to the low prevalence and absence of key market players in this region. However, persisting to countenance invasions from Russian armies, Ukrainian clinics are pushed by rising numbers of deaths and limited medical reserves. There are deficiencies across all kinds of medicine, but restricted access to insulin reserves has guided to an uptick in disorders associated with uncontrolled diabetes. Also, the influence of the import and export of raw materials are anticipated to have little influence over the global basal insulin (long-acting insulin) market growth over the forecast period.

Segment Analysis

The global basal insulin (long-acting insulin) market is segmented based on product type, application, distribution channels and region.

Hospital Pharmacies Segment Accounts for 40% of the Market Share.

Owing to the increasing number of hospitals, the availability of investigational developments, and ease of reimbursement, the hospital pharmacies segment is estimated to hold 42.3% of the global market share. For instance, according to the Republic of Estonia Agency of Medicines, in 2022, the total earning of hospital pharmacies was 137 million euros, with an upsurge of 3% in total compared to previous results.

Geographical Analysis

Europe is Estimated to Hold 28.6% of the Market Share Owing to the Growing Diabetes Prevalence in this Region

Owing to the growing prevalence of diabetes in Europe, the region is estimated to hold the second-largest share accounting for 28.6% of the global basal insulin (long-acting insulin) market. For instance, according to the World Health Organization, there are approximately 60 million individuals with diabetes in the European Region, or roughly 10.3% of males and 9.6% of females aged 25 years and above. The preponderance of diabetes is rising among all ages in the European Region, principally because of additions in overweight and obesity, harmful diet, and physical laziness.

Competitive Landscape

The major global players in the basal insulin (long-acting insulin) market include: Novo Nordisk AS, Sanofi Aventis, Biocon, Julphar, Pfizer, Ganli Pharmaceutical Co., Ltd, Mylan, Wockhardt, and Eli Lily among others.

Why Purchase the Report?

• To visualize the global basal insulin (long-acting insulin) market segmentation based on product type, application, distribution channels and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of basal insulin (long-acting insulin) market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global basal insulin (long-acting insulin) market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies